ACT-777991
ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11[1].
Product Specifications
CAS Number
[1967811-46-6]
UNSPSC
12352005
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/act-777991.html
Purity
99.86
Solubility
10 mM in DMSO
Smiles
OCC[C@@H](N(C(CN1C=NC(C)=N1)=O)CC2)CN2C(SC(C(F)(F)F)=N3)=C3C4=CN=C(C(F)(F)F)N=C4
Molecular Formula
C20H20F6N8O2S
Molecular Weight
550.48
References & Citations
[1]Meyer EA, et al. Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. J Med Chem. 2023 Mar 23;66 (6) :4179-4196.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CXCR3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
I7661-38C-HRP 100 µL
Integrin, beta1, active (ITGB1, Integrin, beta 1 (Fibronectin Receptor, beta Polypeptide, Antigen CD29 includes MDF2, MSK12), CD29, Fibronectin Receptor Subunit beta, FNRB, GPIIA, MDF2, MSK12, VLA-4 Subunit beta, VLAB, VLA-BETA) (HRP)
Ask
View Details